Arcellx Therapeutics (ACLX): Price-to-Projected Revenue Ratio

Arcellx Therapeutics (ACLX) - corporate logo

Arcellx is a rapidly growing leader in oncohematology with an impeccable scientific reputation. The company's forward P/S confirms this market optimism, where the 298.60 figure expresses the state of the metric. Success is based on the proprietary D-Domain, which reduces the toxicity of CAR-T therapy. Process efficiency is complemented by a streamlined express delivery system for biomaterials under strict temperature control.

arcellx.com - ACLX Forward Price-to-Revenue Multiple (period 05/14/2023 - 05/09/2026)

Arcellx Therapeutics (ACLX) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price Arcellx, Inc.|ACLX - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Arcellx Therapeutics|ACLX - Value Adjusted for Debt and Cash
- book value of equity indicators:
Book Value per Share Arcellx|ACLX - Company Net Assets|Market Capitalization to Book Value Ratio arcellx.com|ACLX - Company Assets
- debt and solvency information:
Debt to Equity Arcellx|ACLX - Long-Term Debt to Equity|Short-Term Debt to Equity Arcellx|ACLX - Company Debts|Debt to Book Value Arcellx Therapeutics|ACLX - Company Long-Term Indebtedness|Company Short-Term Debts Arcellx|Quick Ratio arcellx.com
- financial results and valuation multiples details:
ACLX - Net Income|Expected Profit Arcellx|ACLX - Price to Earnings Ratio|Projected Price to Earnings Arcellx Corp|ACLX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Arcellx Therapeutics|ACLX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Arcellx|ACLX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months arcellx.com|ACLX - Earnings per share growth this year|Earnings growth forecast for next year Arcellx
- sales and revenue data:
ACLX - Company Sales|Projected Sales Volume Arcellx, Inc.|ACLX - Price to Sales|Price-to-Projected Revenue Ratio Arcellx Therapeutics
Summary company analytics:Arcellx, Inc. (ACLX)
Original product of Arcellx

The specifics of Arcellx (ACLX) CAR-T therapy lie in the costly manual cell modification cycle, which limits business scalability and drives the high cost of the final product. By analyzing the forward P/S history, an investor compares the current market capitalization with expected revenue to determine the extent to which the market has priced in the future commercial success of the drug and whether the current share price is justified by sales forecasts.

Competitor analysis for Arcellx

Forward P/S Multiple TGTX (TG Therapeutics)|Forward P/S Multiple Disc Medicine Inc IRON|SNDX - Price-to-Projected Revenue Ratio|Forward Price to Sales KURA (Kura)|ADCT: Forward P/S Multiple|Forward Price-to-Revenue Multiple Foghorn Therapeutics Inc.|VOR (Vor Biopharma) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Nkarta Corp NKTX|Price-to-Projected Revenue Ratio Coeptis Therapeutics (COEP)|Price-to-Projected Revenue Ratio ATNM (Actinium Corp)|Price-to-Projected Revenue Ratio Estrella Immunopharma ESLA|CASI Pharmaceuticals Inc. - Price-to-Projected Revenue Ratio|MRKR: Forward Price-to-Revenue Multiple|INAB (IN8bio Inc.) - Market Cap to Projected Revenue|ERNA: Forward P/S Multiple|GT Biopharma Corporation (GTBP) - Forward P/S Multiple|APTO (Aptose Biosciences Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple biopathholdings.com (BPTH)|Price-to-Projected Revenue Ratio MEI Pharma (MEIP)|Price-to-Projected Revenue Ratio VINC (vincerx.com)